Patrick Dempsey Teams up With Breakaway from Cancer(R)

AmgenPatrick Dempsey is speaking out to help connect cancer patients to the free resources available to them via Amgen's Breakaway from Cancer(R) initiative.

"Cancer entered my life in 1997 when my mother was first diagnosed with ovarian cancer," explained Dempsey. "I remember the feelings well - it was overwhelming. My family was trying to come to terms with the fear and shock of the diagnosis, while also working to sort through vast amounts of information to try and make the 'right' decisions for my mother's care."

Dempsey first teamed up with Breakaway from Cancer in 2007 to help bring the issue of better supporting patients to the forefront. In 2008, he founded The Patrick Dempsey Center for Cancer Hope & Healing at the Central Maine Medical Center -- the same hospital where Patrick was born and his mother received her cancer treatment.

Patrick Dempsey has now filmed a public service announcement (PSA) to raise awareness of the wide range of resources available to help people fight cancer. In the video, Dempsey talks about the challenges of choosing the right path and making the right choices - and urges people to take advantage of the free resources available via Breakaway from Cancer.

Breakaway from Cancer represents a collaboration between Amgen and four nonprofit partner organizations to connect individuals with support services ranging from cancer prevention, assistance during treatment, and embracing survivorship. The Breakaway from Cancer website provides a 'one-stop shop' of essential resources, including a navigator tool to help maneuver through the complicated maze of online information that currently exists. The tool conducts a targeted search based on user-entered criteria from more than 100 hand-selected credible cancer websites to offer patients the information they need.

Wherever you may be in your cancer journey, Breakaway from Cancer is here to help you find your way," Dempsey explains. "Whether you're newly diagnosed or have finished your treatment, breakawayfromcancer.com has resources you can use - all in one place."

To watch the PSA, visit http://www.breakawayfromcancer.com.

About Breakaway from Cancer(R)
Founded in 2005 by Amgen, Breakaway from Cancer(R) is a national initiative to increase awareness of important resources available to people affected by cancer - from prevention through survivorship. Through Breakaway from Cancer, Amgen has joined forces with four nonprofit partner organizations: Prevent Cancer Foundation, Cancer Support Community (formerly known as The Wellness Community), Patient Advocate Foundation, and National Coalition for Cancer Survivorship. These organizations offer a broad range of support services complementing those provided by a patient's team of healthcare professionals.

About Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...